Metformin and pioglitazone exerted their beneficial effects without adverse metabolic effects, indicated by no changes in body weight during or after the treatment
Rare but serious risks include pancreatitis symptoms and gallbladder complications, which occur at all dose levels but may be more common with higher cumulative exposure
Sections were incubated in primary antibodies (rabbit anti-MAP2 at 1:750, Thermo Fisher PA5-17646
Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies
Here are a few options to consider: Tirzepatide-based alternatives Tirzepatide is the active ingredient in Zepbound and Mounaro
Options include phentermine (stimulant-based appetite suppressant), naltrexone-bupropion (affects brain reward pathways), or non-medication approaches like diet, exercise, and behavioral therapy